Table (1): the clinicopathological features of the studied breast cancer patients

Parameter	No (%)
Tumor Stage	
1	**4 (6.7)**
2	**4 (6.7)**
3	**27 (45%)**
4	**25 (41.6)**
Tumor Grade	
1	**8 (13.3)**
2	**14 (23.3)**
3	**38 (63.4)**
Pathological Type	
Invasive Ductal Carcinoma	**52 (86.7)**
lobular carcinoma	**8 (13.3)**
Estrogen Receptor positivity	
Negative	**39 (65)**
Positive	**21 (35)**
Progesterone Receptor positivity	
Negative	**28 (46.7)**
Positive	**32 (53.3)**
Metastasis	
No	**36 (60)**
Yes	**24 (40)**
Lymph node	
No	**8 (13.3)**
Yes	**52 (86.7)**

Table(2): Univariate binary logistic regression analysis of polymorphism in predicting breast cancer

Characteristics	Cases	Control	OR (CI $_{95\%}$)	P - value
GC+CC	**25 (41.7%)**	**6 (15%)**	**4.05 (1.48 – 11.09)**	**0.007***
GG	**35 (58.3%)**	**34 (85%)**	**1**	

Table (3): comparison between cases and control groups regarding Survivin alleles.

Parameter	Cases	Control	P-value
Survivin alleles			
C	**29 (24.2%)**	**6 (7.5%)**	**0.002***
G	**91 (75.8%)**	**74 (92.5%)**	

Table (4): Comparison between cases and control groups regarding the polymorphism

Parameter	Cases	Control	P-value
GC+CC GG	25 (41.7%) 35 (58.3%)	6 (15%) 34 (85%)	0.005*

Table (5): comparison between cases and control groups regarding age, family history and hormonal therapy

Parameter	Cases (N= 60)	Control (N= 40)	P-value
Age ≤ 50 years > 50 years	 37 (61.7%) 23 (38.3%)	 28 (70%) 12 (30%)	0.392
Age (years) Mean± S.D. Median (Range)	 48.72 ± 4.94 48.5 (40 – 57)	 47.55 ± 4.76 45.5 (40 – 56)	0.252**
Hormonal therapy No Yes	 28 (46.7%) 32 (53.3%)	 22 (55%) 18 (45%)	0.414
Family history No Yes	 55 (91.7%) 5 (8.3%)	 36 (90%) 4 (10%)	1*

Table (6): The relation between age and Survivin genotypes

Parameter	CC gene (N= 4)	GC gene (N= 21)	GG gene (N= 35)	P-value
Age ≤ 50 years > 50 years	 4 (100%) 0 (0.0%)	 19 (90.5%) 2 (9.5%)	 14 (40%) 21 (60%)	<0.001
Age (years) Mean± S.D. Median (Range)	 41 ± 1.16 41 (40– 42)	 45.48 ± 3.67 44 (43– 56)	 51.54 ± 3.55 52 (45 – 57)	<0.001*

Table (7): comparison between cases and control groups regarding p53 antibodies level and Survivin genotypes.

Parameter	Cases (N= 60)	Control (N= 40)	P-value
p53 (ng/ml) Mean± S.D. Median (Range)	 11.67 ± 11.96 5 (4 – 38)	 4.65 ± 0.48 5 (4 – 5)	0.025
Survivin genes CC GC GG	 4 (6.7%) 21 (35%) 35 (58.3%)	 0 (0.0%) 6 (15%) 34 (85%)	0.013*

Table (8): Receiver operating characteristic (ROC) curve of p53 (ng/ml) for optimum cut off point in predicting breast cancer

Marker	Cutoff	AUC	CI	Sensitivity	Specificity	PPV	NPV	P-value
p53 (ng/ml)	> 5	0.62	0.517 - 0.715	26.67	100	100	47.6	0.015*